Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, Hibsh D, Kozol R, Efroni S, Ricken G, Wöhrer A, Haberler C, Hainfellner J, Krumpl G, Felzmann T, Dohnal AM, Marosi C, Visus C. Erhart F, et al. Among authors: visus c. Acta Neuropathol Commun. 2018 Dec 5;6(1):135. doi: 10.1186/s40478-018-0621-2. Acta Neuropathol Commun. 2018. PMID: 30518425 Free PMC article. Clinical Trial.
Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.
Erhart F, Weiss T, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Blauensteiner B, Lötsch D, Spiegl-Kreinecker S, Berger W, Sialana FJ, Lubec G, Felzmann T, Dohnal A, Visus C. Erhart F, et al. Among authors: visus c. Cytotherapy. 2019 Jun;21(6):643-658. doi: 10.1016/j.jcyt.2019.03.002. Epub 2019 Apr 8. Cytotherapy. 2019. PMID: 30975602
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.
Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Hoffermann M, Ruckser R, Rössler K, Spiegl-Kreinecker S, Fischer MB, Czech T, Visus C, Krumpl G, Felzmann T, Marosi C. Buchroithner J, et al. Among authors: visus c. Cancers (Basel). 2018 Oct 5;10(10):372. doi: 10.3390/cancers10100372. Cancers (Basel). 2018. PMID: 30301187 Free PMC article.
Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature.
Erhart F, Blauensteiner B, Zirkovits G, Printz D, Soukup K, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Lötsch D, Spiegl-Kreinecker S, Berger W, Visus C, Dohnal A. Erhart F, et al. Among authors: visus c. J Cell Mol Med. 2019 Jan;23(1):281-292. doi: 10.1111/jcmm.13927. Epub 2018 Nov 22. J Cell Mol Med. 2019. PMID: 30467961 Free PMC article.
Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.
Erhart F, Hackl M, Hahne H, Buchroithner J, Meng C, Klingenbrunner S, Reitermaier R, Fischhuber K, Skalicky S, Berger W, Spiegl-Kreinecker S, Lötsch D, Ricken G, Kuster B, Wöhrer A, Widhalm G, Hainfellner J, Felzmann T, Dohnal AM, Marosi C, Visus C. Erhart F, et al. Among authors: visus c. NPJ Vaccines. 2020 Jan 16;5(1):5. doi: 10.1038/s41541-019-0149-x. eCollection 2020. NPJ Vaccines. 2020. PMID: 31969991 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33446641
Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Schuler PJ, et al. Among authors: visus c. Clin Cancer Res. 2014 May 1;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583792 Free PMC article. Clinical Trial.
Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer.
Mayordomo JI, Andres R, Isla MD, Murillo L, Cajal R, Yubero A, Blasco C, Lasierra P, Palomera L, Fuertes MA, Güemes A, Sousa R, Garcia-Prats MD, Escudero P, Saenz A, Godino J, Marco I, Saez B, Visus C, Asin L, Valdivia G, Larrad L, Tres A. Mayordomo JI, et al. Among authors: visus c. Tumori. 2007 Jan-Feb;93(1):26-30. doi: 10.1177/030089160709300106. Tumori. 2007. PMID: 17455868 Clinical Trial.
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN. Rahma OE, et al. Among authors: visus c. Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17. Cancer Immunol Immunother. 2012. PMID: 21927947 Free PMC article. Clinical Trial.
25 results